Application of Molecular Biology to the Diagnosis of Viral Hepatitis
Stéphane Chevaliez
National Reference Center for Viral Hepatitis B, C and D, Department of Virology, Hôpital Henri Mondor, Université Paris-Est, Créteil, France
Search for more papers by this authorChristophe Rodriguez
National Reference Center for Viral Hepatitis B, C and D, Department of Virology, Hôpital Henri Mondor, Université Paris-Est, Créteil, France
Search for more papers by this authorJean-Michel Pawlotsky
National Reference Center for Viral Hepatitis B, C and D, Department of Virology, Hôpital Henri Mondor, Université Paris-Est, Créteil, France
Search for more papers by this authorStéphane Chevaliez
National Reference Center for Viral Hepatitis B, C and D, Department of Virology, Hôpital Henri Mondor, Université Paris-Est, Créteil, France
Search for more papers by this authorChristophe Rodriguez
National Reference Center for Viral Hepatitis B, C and D, Department of Virology, Hôpital Henri Mondor, Université Paris-Est, Créteil, France
Search for more papers by this authorJean-Michel Pawlotsky
National Reference Center for Viral Hepatitis B, C and D, Department of Virology, Hôpital Henri Mondor, Université Paris-Est, Créteil, France
Search for more papers by this authorHoward C. Thomas BSc, PhD, FRCP, FRCPath, FMedSci
Emeritus Professor of Hepatology, Department of Medicine, Imperial College London, London, UK
Search for more papers by this authorAnna S.F. Lok MD
Alice Lohrman Andrews Research Professor in Hepatology, Director of Clinical Hepatology, Professor of Internal Medicine, Associate Chair for Clinical Research, Department of Internal Medicine, University of Michigan Health System, Ann Arbor, MI, USA
Search for more papers by this authorStephen A. Locarnini MBBS, BSc(Hons), PhD, FRCPath
Head, Research & Molecular Development, Victorian Infectious Diseases Reference Laboratory, Melbourne, VIC, Australia
Search for more papers by this authorArie J. Zuckerman MD, DSc, FRCP, FRCPath, FMedSci
Emeritus Professor of Medical Microbiology, Formerly Principal and Dean, Royal Free Hospital School of Medicine
Search for more papers by this authorSummary
Molecular biology techniques are used routinely to diagnose and monitor treatment of chronic viral infections such as hepatitis B and hepatitis C, but also now hepatitis D and E. These tools serve mainly to detect and quantify viral genomes, and also to analyze their sequence, in order to determine their genotype or subtype and to identify clinically relevant nucleotide or amino acid substitutions such as those associated with resistance to antiviral drugs. New methods are now available for detecting and quantifying viral genomes and for analyzing their nucleotide and amino acid sequences. The available molecular biology methods and their current clinical applications to hepatitis B, C, D, and E virus infections are reviewed.
References
- European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009; 50: 227–242.
- European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2011; 55: 245–264.
- Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011; 54: 1433–1444.
- Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 1335–1374.
- Liaw YF, Leung N, Kao JH, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2008; 2: 263–283.
- Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 661–662.
- Sanger F, Air GM, Barrell BG, et al. Nucleotide sequence of bacteriophage phi X174 DNA. Nature 1977; 265: 687–695.
- Prober JM, Trainor GL, Dam RJ, et al. A system for rapid DNA sequencing with fluorescent chain-terminating dideoxynucleotides. Science 1987; 238: 336–341.
- Smith LM. High-speed DNA sequencing by capillary gel electrophoresis. Nature 1991; 349: 812–813.
- Metzker ML. Sequencing technologies – the next generation. Nat Rev Genet 2010; 11: 31–46.
- Jardi R, Rodriguez-Frias F, Buti M, et al. Usefulness of dried blood samples for quantification and molecular characterization of HBV DNA. Hepatology 2004; 40: 133–139.
- Tuaillon E, Mondain AM, Meroueh F, et al. Dried blood spot for hepatitis C virus serology and molecular testing. Hepatology 2010; 51: 752–758.
- Chevaliez S, Bouvier-Alias M, Laperche S, Hezode C, Pawlotsky JM. Performance of version 2.0 of the Cobas AmpliPrep/Cobas TaqMan real-time PCR assay for hepatitis B virus DNA quantification. J Clin Microbiol 2010; 48: 3641–3647.
- Thibault V, Pichoud C, Mullen C, et al. Characterization of a new sensitive PCR assay for quantification of viral DNA isolated from patients with hepatitis B virus infections. J Clin Microbiol 2007; 45: 3948–3953.
- Chen CF, Lee WC, Yang HI, et al. Changes in serum levels of HBV DNA and alanine aminotransferase determine risk for hepatocellular carcinoma. Gastroenterology 2011; 141: 1240–1248.
- Chen CJ, Yang HI, Iloeje UH. Hepatitis B virus DNA levels and outcomes in chronic hepatitis B. Hepatology 2009; 49: S72–S84.
- Buster EH, Janssen HL. The importance of HBV genotype in HBeAg-positive chronic hepatitis B patients in whom sustained response is pursued. J Hepatol 2011; 54: 395–396.
- Raimondi S, Maisonneuve P, Bruno S, Mondelli MU. Is response to antiviral treatment influenced by hepatitis B virus genotype? J Hepatol 2010; 52: 441–449.
- Woo G, Tomlinson G, Nishikawa Y, et al. Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-analyses. Gastroenterology 2010; 139: 1218–1229.
- Zoutendijk R, Reijnders JG, Brown A, et al. Entecavir treatment for chronic hepatitis B: adaptation is not needed for the majority of naive patients with a partial virologic response. Hepatology 2011; 54: 443–451.
- Pawlotsky JM, Dusheiko G, Hatzakis A, et al. Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach. Gastroenterology 2008; 134: 405–415.
- Chevaliez S, Bouvier-Alias M, Brillet R, Pawlotsky JM. Overestimation and underestimation of hepatitis C virus RNA levels in a widely used real-time polymerase chain reaction-based method. Hepatology 2007; 46: 22–31.
- Chevaliez S, Bouvier-Alias M, Pawlotsky JM. Performance of the Abbott real-time PCR assay using m2000sp and m2000rt for hepatitis C virus RNA quantification. J Clin Microbiol 2009; 47: 1726–1732.
- Paba P, Fabeni L, Perno CF, Ciotti M. Performance evaluation of the Artus hepatitis C virus QS-RGQ assay. J Virol Meth 2012; 179: 77–80.
- Chevaliez S, Bouvier-Alias M, Castera L, Pawlotsky JM. The Cobas AmpliPrep-Cobas TaqMan real-time polymerase chain reaction assay fails to detect hepatitis C virus RNA in highly viremic genotype 4 clinical samples. Hepatology 2009; 49: 1397–1398.
- Chevaliez S, Fix J, Soulier A, Pawlotsky JM. Underestimation of hepatitis C virus genotype 4 RNA levels by the CobasAmpliPrep/CobasTaqMan assay. Hepatology 2009; 50: 1681.
- Vermehren J, Colucci G, Gohl P, et al. Development of a second version of the Cobas AmpliPrep/Cobas TaqMan hepatitis C virus quantitative test with improved genotype inclusivity. J Clin Microbiol 2011; 49: 3309–3315.
- Chevaliez S, Bouvier-Alias M, Brillet R, Pawlotsky JM. Hepatitis C virus (HCV) genotype 1 subtype identification in new HCV drug development and future clinical practice. PLoS One 2009; 4: e8209.
- Clark PJ, Thompson AJ. Host genomics and HCV treatment response. J Gastroenterol Hepatol 2012; 27: 212–222.
- Moreno C, Deltenre P, Pawlotsky JM, Henrion J, Adler M, Mathurin P. Shortened treatment duration in treatment-naive genotype 1 HCV patients with rapid virologic response: a meta-analysis. J Hepatol 2010; 52: 25–31.
- Diago M, Shiffman ML, Bronowicki JP, et al. Identifying hepatitis C virus genotype 2/3 patients who can receive a 16-week abbreviated course of peginterferon alfa-2a (40KD) plus ribavirin. Hepatology 2010; 51: 1897–1903.
- von Berg T, Wagner M, Nasser S, et al. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology 2006; 130: 1086–1097.
- Buti M, Lurie Y, Zakharova NG, et al. Randomized trial of peginterferon alfa-2b and ribavirin for 48 or 72 weeks in patients with hepatitis C virus genotype 1 and slow virologic response. Hepatology 2010; 52: 1201–1207.
- Sanchez-Tapias JM, Diago M, Escartin P, et al. Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. Gastroenterology 2006; 131: 451–460.
- Pawlotsky JM. Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus. Hepatology 2011; 53: 1742–1751.
-
Chevaliez S,
Rodriguez C,
Soulier A,
Ahmed-Belkacem A,
Hezode C,
Pawlotsky JM.
Molecular characterization of HCV resistance to telaprevir by means of ultra-deep pyrosequencing: preexisting resistant variants and dynamics of resistant populations.
J Hepatol
2011;
54(Suppl 1):
S30.
10.1016/S0168-8278(11)60069-X Google Scholar
- Sullivan JC, De Meyer S, Bartels DJ, et al. Evolution of treatment-emergent resistant variants in telaprevir phase 3 clinical trials. J Hepatol 2011; 54(Suppl 1): S4.
-
Zeuzem S,
Barnard RJ,
Howe JA, et al.
Boceprevir resistance-associated variants (RAVS) are observed more frequently in HCV (GT1)-infected patients with poor response to peginterferon alpha-2b/ribavirin.
J Hepatol
2011;
54(Suppl 1):
S4–S5.
10.1016/S0168-8278(11)60011-1 Google Scholar
